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Concise Review: Human Embryonic Stem
Cells—What Have We Done? What Are We Doing?
Where Are We Going?
DUSKO ILICa,b CAROLINE OGILVIEc
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ABSTRACT
Human pluripotent stem cells possess remarkable proliferative and developmental capacity and
thus have great potential for advancement of cellular therapy, disease modeling, and drug dis-
covery. Twelve years have passed since the first reported isolation of human embryonic stem
cell lines (hESC), followed in October 2010 by the first treatment of a patient with hESC-based
cellular therapy at the Shepherd Center in Atlanta. Despite seemingly insurmountable chal-
lenges and obstacles in the early days, hESC clinical potential reached application in an extraor-
dinarily short time. Eight currently ongoing clinical trials are yielding encouraging results, and
these are likely to lead to new trials for other diseases. However, with the discovery of induced
pluripotent stem cells (iPSC), disease-specific hESC lines derived from patients undergoing pre-
implantation genetic diagnosis for single gene disorders fell short of expectations. Lack of ethi-
cal controversy made human iPSC (hiPSC) with specific genotypes/phenotypes more appealing
than hESC for drug discovery and toxicology-related studies, and in time, lines from HLA-
homologous hiPSC banks are likely to take over from hESC in clinical applications. Currently,
hESC are indispensable; the results of hESC-based clinical trials will set a gold standard for
future iPSC-based cellular therapy. STEM CELLS 2017;35:17–25
SIGNIFICANCE STATEMENT
hESC-based therapies have now become a reality. However, the development of HLA-
homozygous iPSC banks, such as the one in Japan provide an ethically neutral alternative to
hESC for therapeutic as well as research applications. International guidelines on screening and
application of these iPSC lines will likely lead to complete redundancy of hESC lines at some
point in the future.
INTRODUCTION
Optimism that human embryonic stem cells
(hESC) would provide a virtually unlimited
source of selected cell types for future cell
therapies, as well as drug screening and devel-
opment, has resulted in a considerable pro-
gress in stem cell biology over nearly two
decades since the ﬁrst hESC were derived [1].
However, the controversy over the use of hESC
in research and translational medicine has not
diminished over time. There is a constant clash
between the obligation to protect life and the
obligation to help and save those who are suf-
fering. The very strong opinions on the moral
standing of human embryos have led to the
prohibition of work with hESC in some coun-
tries or, where allowed, this work is tightly
regulated.
CIRCUMVENTING ETHICAL CONTROVERSY—hESC
LINES FROM SINGLE BLASTOMERES
Ethical controversy determined the direction of
early work; this focussed on how to establish
hESC lines without destruction of the embryo.
A team from Advanced Cell Technology, a
Massachusetts-based company, succeeded in
deriving hESC lines from single blastomeres of
cleavage stage embryos [2]. In this proof-of-
principle study the embryos did not survive. To
minimize the number of embryos used, the
embryos were disaggregated and all blasto-
meres were sourced for derivation. In the
follow-up study [3], one or two blastomeres
were biopsied from cleavage stage embryos,
and the remaining embryo was left to develop
to blastocyst stage. This strategy mimicked pre-
implantation genetic diagnosis (PGD), a routine
assisted reproduction procedure for selection of
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healthy embryos for transfer and elimination of the embryos
carrying disease-linked mutations. In spite of addressing the
major ethical concerns, the technique did not become wide-
spread. In the same year that the detailed protocol was pub-
lished [4], two groups generated the ﬁrst human induced
pluripotent stem cell (hiPSC) [5, 6], and all the excitement
around hESC started to fade—hESC were seen almost as an his-
torical anomaly.
Instead of being celebrated as a major achievement, the
technique of hESC-derivation from single blastomeres without
embryo destruction became a center of controversy per se.
Following nearly 50,000 public comments on the published
draft Guidelines for research involving hESCs, the NIH modiﬁed
the deﬁnition of hESCs [7]. hESC “are cells that are derived
from the inner cell mass of blastocyst stage human embryos,
are capable of dividing without differentiating for a prolonged
period in culture, and are known to develop into cells and tis-
sues of the three primary germ layers.” Under these guide-
lines, ﬁve hESC lines derived from single blastomeres by the
Advanced Cell Technology team (MA09, NED1-4) [2, 3] and
ten lines derived at the University of California San Francisco
(UCSFB1-10) [8] were ineligible for review because they were
derived from a preblastocyst stage embryo and therefore,
according to the deﬁnition, are not considered to be hESC
lines [9]. Applications were submitted to the NIH hESC Regis-
try in 2009 and 6 years later the decision is still pending. Par-
adoxically, there were no questions raised when clinical trials
for macular degeneration of retina using MA09-derived retinal
pigment epithelial (RPE) cells were labeled as hESC-based cel-
lular therapy [10].hESC generated without embryo destruction
changed views on hESC patentability in the EU. Following the
Directive 98/44/EC on the Legal Protection of Biotechnological
Inventions [11] the European Patent Ofﬁce (EPO) has
refrained from granting patents for hESC on moral grounds. In
2014, the EPO’s Technical Board of Appeal decided that Chung
et al. [3] provided the ﬁrst disclosure of a method of estab-
lishing hESC lines without destroying a human embryo on 7
February 2008. Since then, only the hESC-related applications
ﬁled before that date were excluded from patentability [12].
hESC LINES CARRYING DISEASE-SPECIFIC MUTATIONS
hESC derived from embryos carrying monogenic inherited dis-
eases or chromosomal aberrations were seen as tools for elu-
cidating the etiology and pathophysiology of disorders. On
that premise more than 100 hESC lines have been derived.
Most of them were listed on either NIH hESC Registry or
Human Pluripotent Stem Cell Registry. The spectrum of dis-
eases was limited by the availability of PGD treatments and
the frequency of the speciﬁc mutations in a given population
(Table 1). The most frequently derived were hESC lines carry-
ing speciﬁc mutations linked to Huntington disease (21 lines
derived in 8 centers), Fragile X syndrome (12 lines derived in
3 centers), cystic ﬁbrosis (12 lines derived in 6 centers), myo-
tonic distrophy (11 lines derived in 6 centers), and Charcot–
Marie–Tooth disease (11 lines derived in 5 centers). In spite
of efforts to make such lines available to the scientiﬁc com-
munity, actual interest did not match the initial enthusiasm. A
relatively modest number of publications in peer-reviewed
journals have described their use as research tools; in fact,
the number of reviews elaborating on opportunities of using
hESC lines carrying speciﬁc disease-linked mutations was sev-
eral times higher than the number of actual research papers.
Ethical issues, the regulatory landscape, and the limited spec-
trum of diseases were all drawbacks of hESC lines that hiPSC
did not have and not surprisingly, disease-speciﬁc hiPSC lines
took over.
CLINICAL GRADE hESC LINES
Clinical grade hESC lines are lines which have been derived
under current Good Manufacturing Practice (cGMP) condi-
tions. The ﬁrst clinical-grade hESC lines were the result of
international efforts. Cryopreserved embryos were donated at
Sydney IVF Ltd., derivation was performed at a cGMP facility
in Brisbane, Australia, and the project was sponsored by the
company ES Cell International, which was at that time based
in Singapore [13]. The research versions of these lines were
available for minimal reimbursement through the A*STAR Sin-
gapore Stem Cell Consortium (SSCC). Despite multimillion
investments in these ﬁrst clinical grade hESC lines, they did
not gain the popularity of the H1 and H9 hESC lines derived
by Thomson et al. [1], and the cells were never used in clini-
cal trials. Since May 2010, the lines are owned by the
California-based company BioTime. The company further char-
acterized the lines at the molecular level and made the data,
including copy number variation and genome sequencing,
publicly available [14].
In the U.K., more than 30 clinical grade hESC lines have
been derived in ﬁve centers across the country as a result of
systematic investment from the Medical Research Council.
The results of molecular karyotyping of 25 UK-derived clinical-
grade hESC lines by whole-genome single nucleotide polymor-
phism array analysis was recently published [15]. Fifteen
unique copy number variants greater than 100 kb and three
copy-neutral regions of loss of heterozygosity greater than 1
Mb were detected in these 25 lines; none of these was asso-
ciated with adaptation to cell culture. The presence of the cul-
ture artefact microduplication of chromosome 20q11.21 was,
however, found at higher passages of four clinical grade hESC
lines. The methodology and the results of testing cell lines for
human viral pathogens has been made available for only 2 of
these 25 lines, KCL033 and KCL034 [16].
Whether further investments into characterization of large
numbers of hESC lines might pay off, only time will tell, espe-
cially with the expanding HLA-homozygous iPSC bank in Japan
for clinical purposes [17]. The bank will contain multiple clini-
cal grade iPSC lines homozygous for three HLA loci: HLA-A, -B,
and -DR. Since autologous iPSC-based cell therapy would be
ﬁnancially prohibitive, the aim is to derive the lines from
donors homozygous for HLA haplotypes that are found in the
Japanese population at a high frequency. The cells derived
from such hiPSC lines will carry a reduced risk of rejection
when transplanted into recipients that are heterozygous for
these haplotypes. Since Japan has a relatively homogenous
ethnic population, the required size of the Japanese HLA-
homozygous iPSC bank seems to be relatively small—about
50 homozygous lines will match >90% of the Japanese popu-
lation [18, 19]. In the ethnically more diverse U.K., among
405 theoretical homozygous HLA combinations, a tissue bank
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Table 1. PGD lines listed hPSC and NIH hESC Registry.
Disease Line
Human pluripotent
stem cell
registry NIH Institution
Adrenoleuko-dystrophy SI-201 RGIe105-A Reproductive Genetics
Institute
USA
UM112-1 PGD NIHhESC-14-0285 University of Michigan USA
UM112-2 PGD NIHhESC-15-0307
Alpha thalassemia GENEA073 NIHhESC-12-0193 Genea Australia
Alport syndrome Lis14_Alport_3 NIHhESC-15-0340 Tel Aviv Sourasky Medi-
cal Center
Israel
Amyotrophic lateral sclerosis;
frontotemporal dementia
UM141-6 PGD NIHhESC-16-0360 University of Michigan USA
Androgen insensitivity Lis07_AIS_1 NIHhESC-15-0334 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis08_AIS_2 NIHhESC-15-0335
Aniridia (PAX6) UM29-2 PGD NIHhESC-12-0164 University of Michigan USA
UM29-3 PGD NIHhESC-12-0165
Becker muscular dystrophy SI-170 RGIe077-A Reproductive Genetics
Institute
USA
Beta Thalassemia SI-158 RGIe066-A Reproductive Genetics
Institute
USA
SI-164 RGIe072-A
OZ-8 IMHe011-A Istanbul Memorial
Hospital
Turkey
KCL035 NIHhESC-13-0227 King’s College London U.K.
Becker muscular dystrophy GENEA058 NIHhESC-12-0199 Genea Australia
BRCA1 GENEA059 NIHhESC-12-0175 Genea Australia
Charcot-Marie-tooth disease
type 1
VUB20_CMT1A VUBe014-A Vrije Universiteit Brussel Belgium
STR-I-315-CMT1a INSRMe015-A INSERM France
HUES PGD 11 NIHhESC-11-0094 Harvard University USA
HUES PGD 12 NIHhESC-11-0095
UM11-1PGD NIHhESC-12-0153 University of Michigan USA
UM59-2 PGD NIHhESC-14-0275
UM59-4 PGD NIHhESC-
16-0357
UM89-3 PGD NIHhESC-16-0358
GENEA064 NIHhESC-12-0174 Genea
GENEA062 NIHhESC-12-0187
GENEA063 NIHhESC-12-0188
Cystic ﬁbrosis KCL003 KCLe003-A King’s College London U.K.
KCL021 NIHhESC-13-0219
KL042 NIHhESC-13-0242
KL043 NIHhESC-13-0243
STR-I-203-CFTR INSRMe008-A INSERM France
STR-I-251-CFTR INSRMe009-A
SI-257 RGIe156-A Reproductive Genetics
Institute
USA
VUB04_CF VUBe004-A Vrije Universiteit Brussel Belgium
VUB22_CF VUBe015-A
HAD 2 HADe002-A Hadassah University
Hospital
Israel
GENEA041 NIHhESC-12-0167 Genea Australia
GENEA040 NIHhESC-12-0171
Duchenne muscular
dystrophy
SI-180 RGIe086-A Reproductive Genetics
Institute
USA
HUES PGD 3 NIHhESC-11-0091 Harvard University USA
Lis48_DMD_6_N NIHhESC-15-0311 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis23_DMD_5 NIHhESC-15-0328
Lis10_DMD_1 NIHhESC-15-0337
Lis11_DMD_2 NIHhESC-15-0338
Lis20_DMD_3 NIHhESC-15-0345
Lis22_DMD_3 NIHhESC-15-0347
Emery-Dreifuss muscular
dystrophy
SI-245 RGIe144-A Reproductive Genetics
Institute
USA
Fabry disease STR-I-171-GLA INSRMe004-A INSERM France
Facioscapulohumeral muscu-
lar dystrophy
VUB09_FSHD VUBe009-A Vrije Universiteit Brussel Belgium
GENEA024 NIHhESC-12-0170 Genea Australia
GENEA049 NIHhESC-12-0183
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Table 1. Continued
Disease Line
Human pluripotent
stem cell
registry NIH Institution
GENEA050 NIHhESC-12-0184
GENEA096 NIHhESC-14-0244
Factor VIII deﬁciency HAD 3 HADe003-A Hadassah University
Hospital
Israel
Familial adenomatous
polyposis
STR-I-305-APC INSRMe014-A INSERM France
STR-I-355-APC INSRMe017-A
STR-I-359-APC INSRMe018-A
Lis34_FAP_3 NIHhESC-15-0324 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis34_FAP_2 NIHhESC-15-0325
Lis25_FAP_1 NIHhESC-15-0349
Fanconi’s anemia SI-128 RGIe040-A Reproductive Genetics
Institute
USA
Fragile X syndrome WCMC-37 NIHhESC-13-0211 Weill Cornell Medical
College
USA
UM139-2 PGD NIHhESC-14-0292 University of Michigan USA
Lis 51_FXS9_N NIHhESC-15-0309 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis39_FXS8_N NIHhESC-15-0319
Lis38_FXS7_N NIHhESC-15-0320
Lis37_FXS10_N NIHhESC-15-0321
Lis29_FXS_7 NIHhESC-15-0326
Lis01_HEFX1 NIHhESC-15-0329
Lis02_FXS_2 NIHhESC-15-0330
Lis03_FXS_4 NIHhESC-15-0331
Lis24_FXS_5 NIHhESC-15-0348
Lis26_FXS_6 NIHhESC-15-0350
Hemophilia B UM9-1PGD NIHhESC-12-0154 University of Michigan USA
Hereditary multiple
exostoses
ES-11EM ESe026-A Spanish Stem Cell Bank Spain
GENEA097 NIHhESC-14-0248 Genea Australia
GENEA098 NIHhESC-14-0249
Huntington’s disease SI-186 RGIe091-A Reproductive Genetics
Institute
USA
SI-187 RGIe092-A
SI-194 RGIe098-A
VUB05_HD VUBe005-A Vrije Universiteit Brussel Belgium
VUB28_HD_MFS VUBe018-A
STR-I-155-HD INSRMe003-A INSERM France
KCL005 KCLe004-A King’s College London U.K.
KCL012 KCLe009-A NIHhESC-13-0213
KCL013 KCLe010-A NIHhESC-13-0214
KCL027 NIHhESC-13-0223
KCL036 NIHhESC-13-0241
KCL028 NIHhESC-13-0224
HUES PGD 16 NIHhESC-12-0150 Harvard University USA
UM17-1 PGD NIHhESC-12-0160 University of Michigan USA
GENEA017 NIHhESC-12-0166 Genea Australia
GENEA018 NIHhESC-12-0169
GENEA046 NIHhESC-12-0180
GENEA090 HhESC-14-0245
GENEA091 HhESC-14-0246
GENEA089 HhESC-14-0247
HS799 NIHhESC-13-0207 Sweden
Hydrocephaly Lis50_Hydrocephaly_3_N NIHhESC-15-0308 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis49_Hydrocephaly_2_N NIHhESC-15-0310
Lis35_Hydrocephaly_1 NIHhESC-15-0323
Hydroxysteroid dehydroge-
nase 4 deﬁciency
UM15-4 PGD NIHhESC-12-0161 University of Michigan USA
Hypertrophic cardiomyopa-
thy (MYBPC3)
UM38-2 PGD NIHhESC-12-0155 University of Michigan USA
Hypochondroplasia GENEA077 NIHhESC-12-0261 Genea Australia
Incontinentia pigmenti GENEA071 NIHhESC-12-0191 Genea Australia
Infantile neuroaxonal
dystrophy
GENEA065 NIHhESC-12-0200 Genea Australia
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Table 1. Continued
Disease Line
Human pluripotent
stem cell
registry NIH Institution
Ichthyosis Lis NIHhESC- Tel Aviv Israel
46_Ichthyosis_2_N 15-0313 Sourasky Medical Center
Lis 45_Ichthyosis_1_N NIHhESC-15-0314
Juvenile retinoschisis GENEA072 NIHhESC-12-0192 Genea Australia
Klinefelter’s syndrome Royan H4 Rie004-A Royan Institute Iran
KCL008 KCLe007-A King’s College London U.K.
FC018 CEBe001-A Cellartis Sweden
BG01V VIACe001-A-2 Viacyte (Novocell) USA
WA16 WISCe002-A NIHhESC-11-0097 University of Wisconsin USA
Leuko-encephalopathy Lis 41_LTBL_N NIHhESC-15-0317 Tel Aviv Sourasky Medi-
cal Center
Israel
Loeys-Dietz syndrome 2 GENEA083 NIHhESC-14-0256 Genea Australia
GENEA084 NIHhESC-14-0257
Marfan syndrome SI-154 RGIe062-A Reproductive Genetics
Institute
USA
STR-I-301-MFS INSRMe013-A INSERM France
VUB08_MFS VUBe008-A Vrije Universiteit Brussel Belgium
MFS5 NIHhESC-10-0052 Stanford University USA
UM89-1 PGD NIHhESC-14-0276 University of Michigan USA
UM89-4 PGD NIHhESC-16-0359
Merosin deﬁciency 1A GENEA081 NIHhESC-14-0255 Genea Australia
Multiple endocrine neopla-
sia-type 2A
STR-I-209-MEN2a INSRMe006-A INSERM France
STR-I-211-MEN2a INSRMe007-A
UM57-1 PGD NIHhESC-13-0208 University of Michigan USA
Myotonic dystrophy VUB03_DM1 VUBe003-A Vrije Universiteit Brussel Belgium
VUB19_DM1 VUBe013-A
VUB24_DM1 VUBe017-A
HAD 1 HADe001-A Hadassah University
Hospital
Israel
SI-148 RGIe057-A Reproductive Genetics
Institute
USA
SI-153 RGIe061-A
KCL018 KCLe014-A NIHhESC-12-0218 King’s College London U.K.
GENEA066 NIHhESC-12-0189 Genea Australia
GENEA067 NIHhESC-12-0190
Lis12_DM_1 NIHhESC-15-0339 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis19_DM_2 NIHhESC-15-0344
Nemaline myopathy 2 GENEA078 NIHhESC-14-0252 Genea Australia
GENEA079 NIHhESC-14-0253
GENEA080 NIHhESC-14-0254
Neuroﬁbromatosis SI-137 RGIe049-A Reproductive Genetics
Institute
USA
SI-138 RGIe050-A
SI-139 RGIe051-A
SI-140 RGIe052-A
SI-235 RGIe134-A
KCL024 NIHhESC-12-0220 King’s College London U.K.
KCL025 NIHhESC-12-0221
Lis 47_NF1_2_N NIHhESC-15-0312 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis 42_NF1_1_N NIHhESC-15-0316
Nonsyndromic deafness Lis43_connexin_3_N NIHhESC-15-0315 Tel Aviv Sourasky Medi-
cal Center
Israel
Lis17_Connexin_1 NIHhESC-15-0342
Lis18_Connexin_2 NIHhESC-15-0343
Noonan syndrome Lis21_Noonan_1 NIHhESC-15-0346 Tel Aviv Sourasky Medi-
cal Center
Israel
Osteogenesis imperfecta VUB23_OI VUBe016-A Vrije Universiteit Brussel Belgium
Patau syndrome (trisomy 13) SA002 CEBe034-A Cellartis Sweden
Miz-hES13 MIZMe015-A MizMedi Hospital
(MIZM)
South Korea
FY-hES-5 GZHMCe001-A The Third Afﬁliated Hos-
pital of Guangzhou
Medical College
People’s
Republic
of China
SA002 NIHhESC-10-0086 Cellartis Sweden
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from 150 selected homozygous HLA-typed volunteers could
match 93% of the population [20]. However, among 10,000
HLA typed organ donors used in the study as a representative
of the UK population, only 2% were identiﬁed as non-White
ethnicity, whereas according to the 2011 census 12.8% of the
population was non-White, which indicates the particular
challenges in identifying suitable donors for the members of
these communities [21].hESC lines, such as H1, MA09, and I6
on which are based most clinical trials today, were not clinical
grade lines from the start. They were derived as research
grade lines and, only later were adapted to cGMP conditions.
Moreover, they were derived and propagated in the presence
of mouse feeder cells and/or bovine serum. Xeno-free tech-
nology was developed later [22–28] and in 2011, a team from
King’s College London derived the ﬁrst eight animal product-
free clinical grade lines [26–28]. The lines are karyotyped at
the molecular level [15]; they are also listed on the NIH hESC
Registry and, therefore, eligible for use in NIH-supported
research. The most recent advance is the use of a cell culture
matrix containing a mixture of human recombinant laminin
(LN)2521 and E-cadherin [29] to derive hESC lines from the
inner cell mass of blastocysts and from single blastomere cells
from cleavage stage embryos without a need to destroy the
embryo. The LN-521/E-cadherin matrix allows clonal deriva-
tion, survival and long-term self-renewal of hESC under
chemically deﬁned animal product-free conditions without
addition of ROCK inhibitors.
All hESC lines do not have equal developmental potential
and that cannot be explained by epigenetic memory as with
hiPSC lines. Some of the hESC lines have propensity toward
mesodermal lineages, whereas other toward endoderm [30].
Thus, a screening of the multiple hESC lines for their differen-
tiation propensity has become a standard approach in selec-
tion of lines for particular clinical trials. The yield of
differentiated cells basically depends on propensity of the
source and the efﬁcacy of differentiation protocol. However,
regardless of differentiation efﬁcacy, unlimited supplies of
hESC or hiPSC would ﬁnally give more desired cell types than
any other source, and therefore make the most of invested
capital.
CLINICAL TRIALS
Spinal Cord Injury
In spite of all the obstacles, which include a 21,000-page
Investigational New Drug (IND) application with the FDA, the
ﬁrst patient was treated with an hESC-based cellular therapy
product, oligodendrocyte progenitor cells 1 (OPC1), in a clini-
cal trial at the Shepherd Center in Atlanta in October 2010,
Table 1. Continued
Disease Line
Human pluripotent
stem cell
registry NIH Institution
UCLA7 NIHhESC-12-0143 USA
Retinitis pigmentosa GENEA085 NIHhESC-14-0250 Genea Australia
Saethre-Chotzen syndrome Lis04_Twist NIHhESC-15-0332 Tel Aviv Sourasky Medi-
cal Center
Israel
Simpson Golabi Behmel
syndrome
GENEA088 NIHhESC-14-0260 Genea Australia
Spinocerebellar ataxia VUB10_SCA7 VUBe010-A Vrije Universiteit Brussel
(VUB)
Belgium
STR-I-221-Sca2 INSRMe010-A INSERM France
UM134-1 PGD NIHhESC-14-0286 University of Michigan USA
Spinal muscular atrophy HUES PGD 1 NIHhESC-12-0148 Harvard University USA
HUES PGD 13 NIHhESC-11-0090
HUES PGD 14 NIHhESC-11-0136
KCL026 NIHhESC-13-0222 King’s College London U.K.
Torsion dystonia GENEA074 NIHhESC-12-0194 Genea Australia
Lis09_DYS_1 NIHhESC-15-0336 Tel Aviv Sourasky Medi-
cal Center
Israel
Tuberous sclerosis 2 GENEA086 NIHhESC-14-0258 Genea Australia
GENEA087 NIHhESC-14-0259
Turner syndrome KCL041 NIHhESC-14-0273 King’s College London U.K.
Vitelliform macular
dystrophy
GENEA069 NIHhESC-12-0181 Genea Australia
GENEA070 NIHhESC-12-0182
Von Hippel-Lindau disease/
syndrome
KCL015 KCLe011-A NIHhESC-13-0215 King’s College London U.K.
KCL016 KCLe012-A NIHhESC-13-0216
KCL017 KCLe013-A NIHhESC-13-0217
GENEA060 NIHhESC-12-0172 Genea Australia
GENEA061 NIHhESC-12-0173 Genea Australia
Wiskott-Aldrich syndrome HUES PGD 2 NIHhESC-12-0195 Harvard University USA
KCL029 NIHhESC-13-0225 King’s College London U.K.
X-kinked myopathy with
excessive autophagy
STR-I-229-MTMX INSRMe011-A
STR-I-231-MTMX INSRMe012-A
Wilm’s tumor GENEA068 NIHhESC-12-0168 Genea Australia
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only 12 years after hESC were isolated for the ﬁrst time [1].
The clinical trial for spinal cord injury, sponsored by Geron, a
California-based company, treated only ﬁve patients. The
treatment did not cause serious adverse events, although
motor or sensory neurological changes were not observed.
The lack of obvious improvement in physical condition clashed
with the high expectations of the public and the company’s
stock dropped nearly 60% in the nine months, from January
to September 2011. In order to stay in business, lack of
investment and support forced the company to end the trial
prematurely and to close their stem cell program [31].
All Geron’s assets were transferred to another Bay Area
company, BioTime and its subsidiary Asterias Biotherapeutics,
in 2013. Supported with a strategic partnership award from
the California Institute for Regenerative Medicine and equity
funding, Asterias reinitiated the clinical trial, and the ﬁrst
patient was treated in Atlanta in June 2015. The study is con-
ducted at a total of up to eight centers in the United States.
The AST-OPC1cells will be tested with three sequential esca-
lating doses, the highest being 20 3 106 cells, in 13 patients
with subacute, C-5 to C-7, neurologically complete cervical
spinal cord injury. In February 2014, Asterias received Orphan
Drug Designation from the U.S. Food and Drug Administration
(FDA) for AST-OPC1, for the treatment of acute spinal cord
injury. Orphan Drug Designation is granted to products that
treat diseases affecting fewer than 200,000 people in the
U.S., and it may provide the sponsor certain beneﬁts and
incentives, including a period of marketing exclusivity of 7
years from the ﬁrst marketing application, if regulatory
approval is received for the designated indication [32].
Macular Degeneration of the Retina
Macular degeneration of the retina is likely to be the ﬁrst
disease that could be, to some extent, successfully treated
with hESC-based therapy. Easy accessibility with minimally
invasive procedures, the subretinal space being immunoprivi-
ledged, and the fact that the stem cell transplant can be
monitored regularly with noninvasive methods for structural
engraftment (spectral-domain optical coherence tomography)
and functional outcome (autoﬂuorescence and visual acuity),
make the eye an ideal target choice for initial hESC/hiPSC-
based cellular therapies. Indeed, there are currently nine
clinical trials with hESC and one with hiPSC-derived RPE cells
[10, 31, 33–35]. The initial results and follow-up with a medi-
an time of 22 months are promising; however, we do not
know how long the effects will last. Over time the hESC-
derived RPE cells might succumb to the pathologically
altered environment of a diseased eye and ameliorate the
condition only temporarily. Nevertheless, using ocular indica-
tions as a target was an ingenious idea and it revived the
ﬁeld after Geron was forced to end the trial for spinal cord
injury.
Diabetes
Clinical trials with hESC/iPSC-based therapy in type I diabetes
have been anticipated for a long time. California company Via-
cyte (formerly known as Novocell) has spent a number of
years developing their glucose-responsive insulin producing
PEC-01 cells as well as Encaptra, an encapsulating drug deliv-
ery system made from porous cell-impermeable membrane.
They are currently tested together as VC-01, islet replacement
product candidate. VC-01 is the ﬁrst stem cell-based treat-
ment for type 1 diabetes to enter clinical testing and the ﬁrst
patient was treated in October 2014 at the University of Cali-
fornia San Diego [31, 36, 37].
Heart Repair
A clinical study of a ﬁbrin patch embedded with hESC-derived
cardiac-committed CD151 ISL-11 progenitors transplanted
into epicardium of the infarcted area and covered with an
autologous pericardial ﬂap commenced in autumn 2014 in
France [31, 38]. Following the treatment, the ﬁrst patient suf-
fering from severe heart failure New York Heart Association
(NYHA) functional Class III improved to NYHA Class I and
remained stable NYHA Class I 6-months after the intervention
[38]. This is the ﬁrst hESC-based clinical trial that originated
outside of the US and that is not driven by a for-proﬁt
company.
hESC-Derived Cancer Vaccine
In 2011, Geron reported the development and modiﬁcation
of hESC-derived dendritic cells with mRNA as a potential
strategy for the induction of T-cell-mediated immunity [39,
40]. With discontinuation of the stem cell program, the
assets related to antigen-presenting dendritic cells GRN-
VAC1 and GRN-VAC2 were transferred to Asterias. GRN-
VAC2, renamed AST-VAC2, are mature hESC-derived dendritic
cells that express a modiﬁed form of telomerase, which per-
mits enhanced stimulation of immune response. In Septem-
ber 2014, Asterias teamed up with the UK charity Cancer
Research UK and its development and commercialization
arm Cancer Research Technology to bring AST-VAC2 into clin-
ical trials in patients with non-small cell lung cancer and in
January 2016 has completed the transfer of its manufactur-
ing processes to Cancer Research UK who will produce AST-
VAC2 under cGMP conditions at their Biotherapeutics Devel-
opment Unit.
THE FUTURE—WHERE WE ARE GOING WITH hESC?
With the development of hiPSC, free of ethical issues [5, 6],
hESC started to lose their unique appeal. Within a few years,
from being an indispensable research tool, hESC dropped to
the level of “gold standard” demonstrating that iPSC are
equally useful for addressing certain research questions [e.g.,
[41–44]]. Only time will show whether they will remain as a
“gold standard” or they will slowly become obsolete. Most
of the issues that are relevant for hESC-based therapy also
apply to iPSC [45]. Therefore, it is logical that the standards
set in hESC-based clinical trials should be applicable to
hiPSC-based clinical trials (e.g., clinical trials in macular
degeneration of retina). Since the key difference between
hESC and hiPSC is the potentially modiﬁed genomic and epi-
genetic state of hiPSC, additional standards such as DNA
methylation analysis and medium-resolution array-compara-
tive genomic hybridization should be applied in hiPSC-based
trials.
Nonuniform epigenome transformation during reprog-
raming is not the only issue that may affect the quality of
hiPSC [46]. hiPSC are derived from adult somatic cells, which
accumulate mutations over the lifespan of the donor [47].
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Speciﬁc genetic and epigenetic footprints inﬂuence the
molecular and functional properties of each hiPSC clone and
might lead to misinterpretation of the results in, for exam-
ple, drug screening studies. This is particularly important in
studies with disease-speciﬁc iPSC lines. With newly discov-
ered relatively precise genome editing techniques such as
clustered regularly-interspaced short palindromic repeats
(CRISPR)/Cas9 [48, 49], it is possible to repair mutations in
disease-speciﬁc hiPSC lines and in such a way generate much
better controls than native non-manipulated hESC. On the
other hand, using CRISPR/Cas9, disease-speciﬁc mutations
can be introduced in normal healthy hESC lines, avoiding a
baggage of accumulated lifetime mutations, which are typical
for disease-speciﬁc hiPSC, as well as preserving the native
DNA methylation footprint of hESC, which is almost never
completely matched in hiPSC.
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